Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Mohamed Eid_2023
Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots
Shots:  Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease   Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…
December 5, 2023
VIEWPOINTS_Betty Woo_2023
In an Insightful Conversation with PharmaShots, Betty Woo Highlights Thermo Fisher’s Cell Therapy Collaboration Program
Shots:   Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio    Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program   Betty believes that through innovation and partnership, they can tap into the full…
November 30, 2023
VIEWPOINTS_Moitreyee Chatterjee-Kishore_2023
Moitreyee Chatterjee-Kishore, in an absorbing conversation with PharmaShots, shares the highlights of the SPOTLIGHT & GLOW study
Shots:   Moitreyee Chatterjee-Kishore, HOD, Immuno-Oncology & Cancer Cell Therapy at Astellas shares insights from the P-III trials (SPOTLIGHT & GLOW)   In SPOTLIGHT and GLOW, zolbetuximab and chemotherapy demonstrated improved PFS and OS vs placebo plus chemotherapy, yielding positive outcomes for patients with advanced gastric or GEJ cancer.   Moitreyee highlights the ongoing clinical trials for the…
November 29, 2023
VIEWPOINTS_Michael Irizarry_2023
Michael Irizarry shares insights from the P-III clinical study of LEQEMBI, for the treatment of Alzheimer’s disease
Shots: Michael Irizarry, Senior VP of Clinical Research and Deputy Chief Clinical Officer, Alzheimer’s Disease and Brain Health at Eisai in a stimulating conversation with PharmaShots Michael shares insights from the P-III clinical study Clarity AD of LEQEMBI for the treatment of Alzheimer’s disease The study highlights that LEQEMBI treatment met the primary endpoint and…
November 27, 2023
VIEWPOINTS_Matthew G. Fishler_2023
Matthew G. Fishler Shares the Highlights of AVEIR DR, the World’s First Dual-Chamber Leadless Pacemaker System
Shots:  Matthew G. Fishler, Chief Engineer and Director of Product Development Abbott’s Cardiac Rythm Management Business, in an insightful conversation with PharmaShots   Matthew shares the highlights of the recently approved AVEIR Dr, the world’s first dual-chamber leadless pacemaker system for patients with slower-than-normal or abnormal heart rhythms   Equipped with i2i™ communication technology, AVIER DR eliminates…
November 20, 2023
VIEWPOINTS_Jane Reed_2023
Jane Reed Highlights the Growing Dependence of NLP to Comply with the Regulatory Guidelines
Shots:  In an invigorating conversation with PharmaShots, Jane Reed discusses the transition from document-driven to data-driven decision-making in the pharmaceutical industry   Jane sheds light on the increasing dependence on AI and ML in regulatory affairs and how it helps pharma companies mitigate errors, discrepancies, and non-compliance   Jane highlights the benefits of NLP in ensuring regulatory…
November 16, 2023
VIEWPOINTS_Micah Litow_2023
Micah Litow shares insights from the 2023 Kalderos Annual Report on drug discount programs
Shots:  Micah Litow, in a stimulating conversation with PharmaShots, shares insights from the 2023 Kalderos Annual Report on drug discount programs   Micah highlights the challenges the drug manufacturers, covered entities, and state payers face on account of US drug discount programs   Micah sheds light on how Kalderos' MDRP Discount Monitoring solution helps drug manufacturers prevent…
November 9, 2023
Load more